-transparent.png){kind=logo}
The effectiveness of clonidine in suppressing the occurrence of postmenopausal hot flashes was examined using a dose-response study design and objective recordings of hot flashes. Patients with frequent flashes were studied before and after oral administration of placebo and 0.1, 0.2, and 0.4 mg of clonidine daily for 2 weeks at each dose level. Finger temperature and skin resistance were recorded as indices of hot flash episodes. Four of 10 subjects beginning the study withdrew because of drug-related side effects. Clonidine was found to reduce significantly the frequency of hot flashes as compared with baseline (P less than .005) and with effects of the placebo (P less than .05). At the maximum dosage the mean rate of hot flash occurrence decreased 46%. It was concluded that clonidine does reduce the frequency of postmenopausal flashes.
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
March 1985,
Fertility and sterility,
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
April 1982,
Obstetrics and gynecology,
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
January 2009,
Menopause (New York, N.Y.),
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
January 2009,
Menopause (New York, N.Y.),
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
January 2002,
Advances in therapy,
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
February 2003,
Obstetrics and gynecology,
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
July 1999,
American journal of obstetrics and gynecology,
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
November 2018,
Menopause (New York, N.Y.),
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
March 2010,
Menopause (New York, N.Y.),
L R Laufer, and
Y Erlik, and
D R Meldrum, and
H L Judd
April 2007,
Maturitas,
